Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks

Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M.D, John E. Bennett, M.D, H. Preston Holley, Jr., M.D, John R. Black, M.D, David A. Stevens, M.D., Branch Fields, M.D, Gary A. Roselle, M.D, John R. Perfect, M.D, Dale N. Gerding, M.D, and Richard E. Horton, M.D

Research output: Contribution to journalArticle

301 Citations (Scopus)

Abstract

One hundred ninety-four patients with cryptococcal meningitis were enrolled in a multicenter, prospective, randomized clinical trial to compare the efficacy and toxicity of four as compared with six weeks of combination amphotericin B and flucytosine therapy. Among 91 patients who met preestablished criteria for randomization, cure or improvement was noted in 75 percent of those treated for four weeks and in 85 percent of those treated for six weeks. The estimated relapse rate for the four-week regimen was higher — 27 as compared with 16 percent — whereas the incidence of toxic effects for the two regimens was similar — 44 as compared with 43 percent. Among 23 transplant recipients, 4 of 5 treated for four weeks relapsed, leading to the decision to treat the rest of the group for six weeks. Only 3 of the 18 treated for six weeks relapsed. In a third group of 80 patients, the protocol was not followed during the initial four weeks, and these patients were not randomized. Thirty-eight died or relapsed. Multifactorial analysis of pretreatment factors for all 194 patients identified three significant predictors (P<0.05) of a favorable response: headache as a symptom, normal mental status, and a cerebrospinal fluid white-cell count above 20 per cubic millimeter. These and other findings in this study are consistent with the view that the four-week regimen should be reserved for patients who have meningitis without neurologic complications, underlying disease, or immunosuppressive therapy; a pretreatment cerebrospinal fluid white-cell count above 20 per cubic millimeter and a serum cryptococcal antigen titer below 1:32; and at four weeks of therapy, a negative cerebrospinal fluid India ink preparation and serum and cerebrospinal fluid cryptococcal-antigen titers below 1:8. Patients who do not meet these criteria should receive at least six weeks of therapy. (N Engl J Med 1987; 317:334–41.), CRYPTOCOCCAL meningitis is the most common form of fungal meningitis in the United States and is an especially important cause of morbidity and mortality among immunocompromised patients. Although various therapeutic regimens have been used in this disease, none has been uniformly effective or without serious toxicity.1,2 In 1979, Bennett and his coinvestigators reported that a regimen combining amphotericin B (0.3 mg per kilogram of body weight per day) and flucytosine (150 mg per kilogram per day) and lasting six weeks was as effective, according to all the criteria studied, as a low-dose regimen of amphotericin B alone (0.4 mg per…

Original languageEnglish (US)
Pages (from-to)334-341
Number of pages8
JournalNew England Journal of Medicine
Volume317
Issue number6
DOIs
StatePublished - Aug 6 1987

Fingerprint

Cryptococcal Meningitis
Flucytosine
Amphotericin B
Cerebrospinal Fluid
Meningitis
Therapeutics
Fungal Meningitis
Cell Count
Antigens
Poisons
Immunocompromised Host
Immunosuppressive Agents
Random Allocation
Serum
Nervous System
Statistical Factor Analysis
Headache
Randomized Controlled Trials
Body Weight
Morbidity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M.D, John E. Bennett, M.D, H. Preston Holley, Jr., M.D, John R. Black, M.D, David A. Stevens, M.D., Branch Fields, M.D, Gary A. Roselle, M.D, John R. Perfect, M.D, Dale N. Gerding, M.D, and Richard E. Horton, M.D (1987). Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks. New England Journal of Medicine, 317(6), 334-341. https://doi.org/10.1056/NEJM198708063170602

Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks. / Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M.D, John E. Bennett, M.D, H. Preston Holley, Jr., M.D, John R. Black, M.D, David A. Stevens, M.D., Branch Fields, M.D, Gary A. Roselle, M.D, John R. Perfect, M.D, Dale N. Gerding, M.D, and Richard E. Horton, M.D.

In: New England Journal of Medicine, Vol. 317, No. 6, 06.08.1987, p. 334-341.

Research output: Contribution to journalArticle

Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M.D, John E. Bennett, M.D, H. Preston Holley, Jr., M.D, John R. Black, M.D, David A. Stevens, M.D., Branch Fields, M.D, Gary A. Roselle, M.D, John R. Perfect, M.D, Dale N. Gerding, M.D, and Richard E. Horton, M.D 1987, 'Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks', New England Journal of Medicine, vol. 317, no. 6, pp. 334-341. https://doi.org/10.1056/NEJM198708063170602
Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M.D, John E. Bennett, M.D, H. Preston Holley, Jr., M.D, John R. Black, M.D, David A. Stevens, M.D., Branch Fields, M.D, Gary A. Roselle, M.D, John R. Perfect, M.D, Dale N. Gerding, M.D, and Richard E. Horton, M.D. Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks. New England Journal of Medicine. 1987 Aug 6;317(6):334-341. https://doi.org/10.1056/NEJM198708063170602
Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M.D, John E. Bennett, M.D, H. Preston Holley, Jr., M.D, John R. Black, M.D, David A. Stevens, M.D., Branch Fields, M.D, Gary A. Roselle, M.D, John R. Perfect, M.D, Dale N. Gerding, M.D, and Richard E. Horton, M.D. / Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks. In: New England Journal of Medicine. 1987 ; Vol. 317, No. 6. pp. 334-341.
@article{7ff316aaa05147029b15947041d9be6f,
title = "Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks",
abstract = "One hundred ninety-four patients with cryptococcal meningitis were enrolled in a multicenter, prospective, randomized clinical trial to compare the efficacy and toxicity of four as compared with six weeks of combination amphotericin B and flucytosine therapy. Among 91 patients who met preestablished criteria for randomization, cure or improvement was noted in 75 percent of those treated for four weeks and in 85 percent of those treated for six weeks. The estimated relapse rate for the four-week regimen was higher — 27 as compared with 16 percent — whereas the incidence of toxic effects for the two regimens was similar — 44 as compared with 43 percent. Among 23 transplant recipients, 4 of 5 treated for four weeks relapsed, leading to the decision to treat the rest of the group for six weeks. Only 3 of the 18 treated for six weeks relapsed. In a third group of 80 patients, the protocol was not followed during the initial four weeks, and these patients were not randomized. Thirty-eight died or relapsed. Multifactorial analysis of pretreatment factors for all 194 patients identified three significant predictors (P<0.05) of a favorable response: headache as a symptom, normal mental status, and a cerebrospinal fluid white-cell count above 20 per cubic millimeter. These and other findings in this study are consistent with the view that the four-week regimen should be reserved for patients who have meningitis without neurologic complications, underlying disease, or immunosuppressive therapy; a pretreatment cerebrospinal fluid white-cell count above 20 per cubic millimeter and a serum cryptococcal antigen titer below 1:32; and at four weeks of therapy, a negative cerebrospinal fluid India ink preparation and serum and cerebrospinal fluid cryptococcal-antigen titers below 1:8. Patients who do not meet these criteria should receive at least six weeks of therapy. (N Engl J Med 1987; 317:334–41.), CRYPTOCOCCAL meningitis is the most common form of fungal meningitis in the United States and is an especially important cause of morbidity and mortality among immunocompromised patients. Although various therapeutic regimens have been used in this disease, none has been uniformly effective or without serious toxicity.1,2 In 1979, Bennett and his coinvestigators reported that a regimen combining amphotericin B (0.3 mg per kilogram of body weight per day) and flucytosine (150 mg per kilogram per day) and lasting six weeks was as effective, according to all the criteria studied, as a low-dose regimen of amphotericin B alone (0.4 mg per…",
author = "{Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M.D, John E. Bennett, M.D, H. Preston Holley, Jr., M.D, John R. Black, M.D, David A. Stevens, M.D., Branch Fields, M.D, Gary A. Roselle, M.D, John R. Perfect, M.D, Dale N. Gerding, M.D, and Richard E. Horton, M.D} and Dismukes, {William E.} and Gretchen Cloud and Gallis, {Harry A.} and Kerkering, {Thomas M.} and Gerald Medoff and Craven, {Philip C.} and Kaplowitz, {Lisa G.} and Fisher, {John F.} and Gregg, {Clark R.} and Fisher, {John Fremont} and Smith Shadomy and Stamm, {Alan M.} and Diasio, {Robert B.} and Leo Kaufman and Soong, {Seng Jaw} and Blackwelder, {William C.}",
year = "1987",
month = "8",
day = "6",
doi = "10.1056/NEJM198708063170602",
language = "English (US)",
volume = "317",
pages = "334--341",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "6",

}

TY - JOUR

T1 - Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six Weeks

AU - Other members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group are Steven G. Alsip M.D., Michael S. Saag, M.D, George H. Karam, M.D, Carol A. Kauffman, M.D, George A. Sarosi, M.D, Robert L. Marier, M.D, W. Michael Scheld, M

AU - Dismukes, William E.

AU - Cloud, Gretchen

AU - Gallis, Harry A.

AU - Kerkering, Thomas M.

AU - Medoff, Gerald

AU - Craven, Philip C.

AU - Kaplowitz, Lisa G.

AU - Fisher, John F.

AU - Gregg, Clark R.

AU - Fisher, John Fremont

AU - Shadomy, Smith

AU - Stamm, Alan M.

AU - Diasio, Robert B.

AU - Kaufman, Leo

AU - Soong, Seng Jaw

AU - Blackwelder, William C.

PY - 1987/8/6

Y1 - 1987/8/6

N2 - One hundred ninety-four patients with cryptococcal meningitis were enrolled in a multicenter, prospective, randomized clinical trial to compare the efficacy and toxicity of four as compared with six weeks of combination amphotericin B and flucytosine therapy. Among 91 patients who met preestablished criteria for randomization, cure or improvement was noted in 75 percent of those treated for four weeks and in 85 percent of those treated for six weeks. The estimated relapse rate for the four-week regimen was higher — 27 as compared with 16 percent — whereas the incidence of toxic effects for the two regimens was similar — 44 as compared with 43 percent. Among 23 transplant recipients, 4 of 5 treated for four weeks relapsed, leading to the decision to treat the rest of the group for six weeks. Only 3 of the 18 treated for six weeks relapsed. In a third group of 80 patients, the protocol was not followed during the initial four weeks, and these patients were not randomized. Thirty-eight died or relapsed. Multifactorial analysis of pretreatment factors for all 194 patients identified three significant predictors (P<0.05) of a favorable response: headache as a symptom, normal mental status, and a cerebrospinal fluid white-cell count above 20 per cubic millimeter. These and other findings in this study are consistent with the view that the four-week regimen should be reserved for patients who have meningitis without neurologic complications, underlying disease, or immunosuppressive therapy; a pretreatment cerebrospinal fluid white-cell count above 20 per cubic millimeter and a serum cryptococcal antigen titer below 1:32; and at four weeks of therapy, a negative cerebrospinal fluid India ink preparation and serum and cerebrospinal fluid cryptococcal-antigen titers below 1:8. Patients who do not meet these criteria should receive at least six weeks of therapy. (N Engl J Med 1987; 317:334–41.), CRYPTOCOCCAL meningitis is the most common form of fungal meningitis in the United States and is an especially important cause of morbidity and mortality among immunocompromised patients. Although various therapeutic regimens have been used in this disease, none has been uniformly effective or without serious toxicity.1,2 In 1979, Bennett and his coinvestigators reported that a regimen combining amphotericin B (0.3 mg per kilogram of body weight per day) and flucytosine (150 mg per kilogram per day) and lasting six weeks was as effective, according to all the criteria studied, as a low-dose regimen of amphotericin B alone (0.4 mg per…

AB - One hundred ninety-four patients with cryptococcal meningitis were enrolled in a multicenter, prospective, randomized clinical trial to compare the efficacy and toxicity of four as compared with six weeks of combination amphotericin B and flucytosine therapy. Among 91 patients who met preestablished criteria for randomization, cure or improvement was noted in 75 percent of those treated for four weeks and in 85 percent of those treated for six weeks. The estimated relapse rate for the four-week regimen was higher — 27 as compared with 16 percent — whereas the incidence of toxic effects for the two regimens was similar — 44 as compared with 43 percent. Among 23 transplant recipients, 4 of 5 treated for four weeks relapsed, leading to the decision to treat the rest of the group for six weeks. Only 3 of the 18 treated for six weeks relapsed. In a third group of 80 patients, the protocol was not followed during the initial four weeks, and these patients were not randomized. Thirty-eight died or relapsed. Multifactorial analysis of pretreatment factors for all 194 patients identified three significant predictors (P<0.05) of a favorable response: headache as a symptom, normal mental status, and a cerebrospinal fluid white-cell count above 20 per cubic millimeter. These and other findings in this study are consistent with the view that the four-week regimen should be reserved for patients who have meningitis without neurologic complications, underlying disease, or immunosuppressive therapy; a pretreatment cerebrospinal fluid white-cell count above 20 per cubic millimeter and a serum cryptococcal antigen titer below 1:32; and at four weeks of therapy, a negative cerebrospinal fluid India ink preparation and serum and cerebrospinal fluid cryptococcal-antigen titers below 1:8. Patients who do not meet these criteria should receive at least six weeks of therapy. (N Engl J Med 1987; 317:334–41.), CRYPTOCOCCAL meningitis is the most common form of fungal meningitis in the United States and is an especially important cause of morbidity and mortality among immunocompromised patients. Although various therapeutic regimens have been used in this disease, none has been uniformly effective or without serious toxicity.1,2 In 1979, Bennett and his coinvestigators reported that a regimen combining amphotericin B (0.3 mg per kilogram of body weight per day) and flucytosine (150 mg per kilogram per day) and lasting six weeks was as effective, according to all the criteria studied, as a low-dose regimen of amphotericin B alone (0.4 mg per…

UR - http://www.scopus.com/inward/record.url?scp=0023181813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023181813&partnerID=8YFLogxK

U2 - 10.1056/NEJM198708063170602

DO - 10.1056/NEJM198708063170602

M3 - Article

VL - 317

SP - 334

EP - 341

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 6

ER -